{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:39:29Z","timestamp":1788676769221,"version":"build-2803163510"},"reference-count":119,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Advances in biotechnology are set to revolutionise the treatment of haematological malignancies. Current treatments have limited efficacy due to their high toxicity and poor long\u2010term outcomes, particularly in acute myeloid leukaemia (AML). In 2024\u20132025, emerging targeted therapies promise improved results with reduced adverse effects. This review is the first of an annual series exploring the latest in\u2010patient developments in several key areas, focusing on mechanisms. We present advances in the use and action of several therapies including epigenetic modulators, protein degraders, apoptotic inducers, gene editing, and immunotherapy. We discuss the individual molecular mechanisms and clinical findings of these developments, emphasising their potential to improve survival and offer renewed hope for individuals with blood cancer. Importantly, such novel approaches with testing in patients should lead to further intensive efforts both at basic and translational research levels aiming at effective targeted and immunotherapy in blood cancers.<\/jats:p>","DOI":"10.1111\/jcmm.70700","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:37:11Z","timestamp":1751852231000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In\u2010Patient Developments 2024\u20132025"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9586-9512","authenticated-orcid":false,"given":"Akbar M.","family":"Shahid","sequence":"first","affiliation":[{"name":"Ludwig Institute for Cancer Research University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Vainchenker","sequence":"additional","affiliation":[{"name":"INSERM UMR1287  Villejuif France"},{"name":"Universit\u00e9 Paris\u2010Saclay  Villejuif France"},{"name":"Gustave Roussy  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research University of Oxford  Oxford UK"},{"name":"Ludwig Institute for Cancer Research  Brussels Belgium"},{"name":"Universit\u00e9 Catholique de Louvain and de Duve Institute  Brussels Belgium"},{"name":"Walloon Excellence in Life Sciences and Biotechnology  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054"},{"key":"e_1_2_13_3_1","unstructured":"Food and Drug Administration \u201cFDA Approves First Gene Therapies to Treat Patients With Sickle Cell Disease \u201d(2023)."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001731\u20104"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596\u2010561"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201013\u20100609"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03579"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010018\u20100469\u20103"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018661"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201004\u2010427"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2016.06.005"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2022.2139067"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14221"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010024\u201007328\u2010w"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073\u2010014\u20100060\u2010z"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092007"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102141.2001.02933.x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2016.12.002"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013215"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s7222"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201052"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.10.024"},{"key":"e_1_2_13_28_1","unstructured":"H.Belaghzal G.Castello Coatti C. W.O'donnell andT.McCauley \u201cProgrammable Epigenomic mRNA Therapeutics Enable Multi\u2010gene Up or Down Tuning of \u03b1\u2010globin via Regulatory Element Targeting: A Precision Approach for \u03b2\u2010 and \u03b1\u2010Thalassemia Treatment\u201d."},{"key":"e_1_2_13_29_1","unstructured":"ClinicalTrials.gov \u201cA Phase 1\/2 Study to Evaluate OTX\u20102022 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene (MYCHELANGELO I) \u201d(2022) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05497453?term=omega&cond=Hepatocellular+Carcinoma&draw=2&rank=1."},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102141.2002.03618.x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000557\u20106"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.025"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax5863"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010023\u201005755\u20109"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198"},{"issue":"234","key":"e_1_2_13_36_1","article-title":"The Novel Menin Inhibitor ZE63\u20100302 has an Impressive Safety Profile and Unique Chemistry that Suggests Improved Efficacy Against Resistance Mutations","volume":"422","author":"Hertlein E.","year":"2024","journal-title":"EHA Library"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201010\u2010604"},{"key":"e_1_2_13_38_1","unstructured":"R. D.Parrondo M. C.Thompson A. M.Frustaci et\u00a0al. \u201cPreliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB\u201016673 in Patients With Relapsed or Refractory CLL\/SLL: Results from the Phase 1 BGB\u201016673\u2010101 Study. Presented at: 2024 European Hematology Association Congress; June 13\u201316 2024; Madrid Spain. Abstract S157\u201d."},{"key":"e_1_2_13_39_1","article-title":"FDA Fast Track Designation for CLL\/SLL","author":"BeiGene's BGB\u201016673 receives U.S","year":"2024","journal-title":"News Release. BeiGene"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2850"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010147"},{"key":"e_1_2_13_42_1","article-title":"Nurix Therapeutics receives U.S. FDA Fast Track Designation for NX\u20105948 for the Treatment of Relapsed or Refractory CLL and SLL","author":"Nurix","year":"2024","journal-title":"News Release. Nurix Therapeutics"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002317\u20104"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/362857a0"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010210354"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101195"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201018\u20101119"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019706"},{"key":"e_1_2_13_49_1","unstructured":"S.Opat M. A.Anderson A.Tedeschi et\u00a0al. \u201cResults From the Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax (SONRO) in Combination With Zanubrutinib (ZANU) for Relapsed\/Refractory (R\/R) CLL\/SLL Show Deep and Durable Responses. Presented at: EHA2024; June 14\u201316 2024; Amsterdam Netherlands. Abstract S156. EHA Library \u201d(2025) https:\/\/ehaweb.org\/."},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010205"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113206"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010023\u201005294\u20103"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3826"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000459\u20107"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102005\u201003\u20101072"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010205"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.311"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450060023004"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010019\u20100210\u2010z"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010022\u201000257\u20102"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010018\u20102198\u20109"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207427"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae165.0360"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201903002R"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1376554"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010024\u201000490\u2010x"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24988"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.R120.002309"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061397"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20941"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403186"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201007\u2010099366"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201023\u20100020"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010021\u201004232\u20105"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1458449"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2394"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523\u20105394.1999.07108.x"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2010024\u201003814\u20102"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102021\u2010003882"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.07.005"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290\u2010022\u201000428\u2010w"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000345"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00889\u20108"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3904"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276\u2010021\u201000576\u20100"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100177"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010023\u201001653\u20108"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010193"},{"key":"e_1_2_13_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201006\u2010782"},{"key":"e_1_2_13_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010681"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201009\u2010671"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201015\u20101434"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201009\u2010874"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010679"},{"key":"e_1_2_13_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_2_13_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024373"},{"key":"e_1_2_13_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026811"},{"key":"e_1_2_13_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010173"},{"key":"e_1_2_13_107_1","doi-asserted-by":"crossref","unstructured":"A.Kuchnio \u201cDiscovery of JNJ\u201088549968 a Novel First\u2010In\u2010Class CALRmutxCD3 T\u2010Cell Engaging Antibody for the Treatment of Myeloproliferative Neoplasms. Presented at: 10th Translational Research Conference Myeloproliferative Neoplasms; April 26\u201328 2024; Mandelieu\u2010La Napoule France\u201d.","DOI":"10.1182\/blood-2023-173430"},{"key":"e_1_2_13_108_1","unstructured":"A.Rampotas \u201cDevelopment of CAR\u2010T Cell Therapy to Selectively Eliminate Calreticulin\u2010Mutant Neoplasms. Presented at: 10th Translational Research Conference Myeloproliferative Neoplasms; April 26\u201328 2024; Mandelieu\u2010La Napoule France\u201d."},{"key":"e_1_2_13_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010021\u201001863\u2010w"},{"key":"e_1_2_13_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3205"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20102180"},{"key":"e_1_2_13_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201023\u20100784"},{"key":"e_1_2_13_114_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001509\u20102"},{"key":"e_1_2_13_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8558"},{"key":"e_1_2_13_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20553"},{"key":"e_1_2_13_117_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091405"},{"key":"e_1_2_13_118_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524017666170220095838"},{"key":"e_1_2_13_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198"},{"key":"e_1_2_13_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.018"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcmm.70700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:10:33Z","timestamp":1756293033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.70700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":119,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/jcmm.70700"],"URL":"https:\/\/doi.org\/10.1111\/jcmm.70700","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70700"}}